Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.53M | -67.66M | -40.91M | -16.21M | -18.61M |
| Total Depreciation and Amortization | 699.00K | 664.00K | 627.00K | 598.00K | 609.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.03M | 53.82M | 27.07M | 1.52M | 3.67M |
| Change in Net Operating Assets | -4.11M | -7.21M | -9.35M | -8.11M | -8.77M |
| Cash from Operations | -18.92M | -20.39M | -22.56M | -22.20M | -23.09M |
| Capital Expenditure | -522.00K | -488.00K | -588.00K | -624.00K | -565.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.94M | 5.00M | 9.00M | 257.00K | -1.74M |
| Cash from Investing | -13.46M | 4.51M | 8.41M | -367.00K | -2.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -59.00K | -58.00K | -55.00K | -55.00K | -54.00K |
| Issuance of Common Stock | 27.77M | 29.30M | 27.23M | 27.35M | 36.11M |
| Repurchase of Common Stock | -81.00K | -80.00K | -80.00K | -15.00K | -23.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -684.00K | -855.00K | -623.00K | -395.00K | -171.00K |
| Cash from Financing | 26.95M | 28.31M | 26.47M | 26.88M | 35.86M |
| Foreign Exchange rate Adjustments | 396.00K | 241.00K | 283.00K | -98.00K | -95.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.03M | 12.67M | 12.61M | 4.22M | 10.36M |